Not only is it possible to detect aneuploidy and structural fetal anomalies with sonography during the first trimester, but doing so allows for better treatment options, according to a study published in the Journal of Ultrasound in Medicine.
Not only is it possible to detect aneuploidy and structural fetal anomalies with sonography during the first trimester, but doing so allows for better treatment options, according to a study published in the Journal of Ultrasound in Medicine.
The standard of care is that aneuploidy can be detected in the second trimester, but it is becoming increasingly clear chromosomal anomalies are identifiable in the first trimester. The current study adds evidence that structural anomalies are identifiable as well.
In their retrospective review led by Dr. Reem Abu-Rustum from the Center for Advanced Fetal Care in Tripoli, Lebanon, the researchers conducted a chart review of women scanned in each trimester.
They included 1370 fetuses in their study and found six cases of aneuploidy were detected, five of which were picked up in the first trimester and later confirmed by karyotype. The researchers found 36 cases of structural fetal anomalies, 16 of which were picked up in the first trimester and later confirmed by second- and third-trimester scans.
“If termination of pregnancy is an option, then the earlier it is accomplished, the less the maternal risks,” Abu-Rustum said. “On the other hand if termination is not elected, then the first-trimester scan now provides invaluable information about the natural lethality of certain conditions.”
In some cases fetuses with certain anomalies will die spontaneously in utero.
“The first-trimester scan is fast becoming a pillar in obstetric care,” Abu-Rustum said. It is beginning to shape the future of prenatal care and the way physicians practice, Abu-Rustum added.
This study demonstrates the possibility that appropriately performed ultrasound in the first trimester could be used to detect aneuploidy earlier than other screening methods such as amniocentesis, said Dr. David Bahner, ultrasound director and an emergency medicine physician at Ohio State University in Columbus.
“The question becomes whether this should be done routinely and what is the appropriate training to perform these types of scans,” he said.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.